ThromBash XRA

Innovation in light transmission aggregometry (LTA): Measurement without autologous PPP

• LTA determines platelet aggregation in platelet-rich plasma (PRP) by assessing the change in light transmission in response to added specific platelet agonists.
• Under constant stirring, agonists, through the activation of specific receptors, can prompt platelet granule secretion, activation, and aggregation.
• The reactivity pattern with various agonists acting through different receptors and signalling pathways helps to establish a diagnosis.
• However, limitations of LTA are obvious: it requires long time and large volumes of blood for the preparation of PRP and autologous platelet-poor plasma (PPP), which is necessary as reference for calibrating the measurement zero.
• A novel feature is the ability of ThromBash XRA to measure LTA in PRP not only against autologous PPP but also against a virtual reference.

Retrospectively calculation of measurements

• For validation in your laboratory, all results can be subsequently calculated in relation to the different references, PPP / VPPP.
• All results obtained against autologous PPP can be recalculated retrospectively with VPPP based on PRP data stored in the database.
• For all results obtained with VPPP, the autologous PPP can be measured retrospectively, the results of the PRP data stored in the database are recalculated using this autologous PPP as reference.

• Comparison between TXRA PPP (= traditional LTA) against the VPPP method (without autologous PPP). Individual results from 47 patients tested with seven different reagents (329 individual data points) are shown with either PPP or VPPP as the reference. Pearson’s correlation coefficient (R2) is 0.9849.

Virtual Platelet-Poor Plasma Reference

• ThromBash XRA employs a patented method to reconstruct the optical properties of a fictive autologous PPP, called “virtual” platelet-poor plasma (VPPP).This VPPP corrects the spectral properties of a PRP that it resembles autologous PPP by analysis of its spectral properties according to a novel complex proprietary algorithm.
• Performing LTA from platelet-rich plasma without requiring autologous PPP, simplifies LTA, saves time, costs, and material.
• Beyond a relevant reduction in workload, this novel feature has also the potential of reducing total blood volume, an advantage for children, but also for patients in general.

• LTA 1 reagent with aggregation inductors Arachidonic acid (AA), Adenosine diphosphate (ADP), Collagen (Col), Epinephrine (EPI) and Thrombin receptor-activating peptide (TRAP) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP).
• Standardized reagent combination for screening
• Inductor concentrations according to ISTH recommendation
• Lyophilized Arachidonic acid (AA) 20 mM with test application AA 1 mM.
• Lyophilized Adenosine diphosphate (ADP) 100 µM with test application ADP 2.5 µM.
• Lyophilized Collagen (Col) 50 µg/ml with test application Col 2 µg/ml.
• Lyophilized Epinephrine (EPI) 100 µM with test application Epi 5 µM.
• Lyophilized Thrombin receptor-activating peptides (TRAP) 500 µM with test application TRAP 10 µM.
• Diluent, Cleaning solution, cuvettes and balls enclosed in the kit.
• Sufficient for 70 screens
• Stability (reconstituted): 28 days at 2–8°C
• 2 x LTA 1 Reagent Tray (5 x 1 ml)
  2 x LTA Diluent 20 ml
  2 x Clean Pro 15 ml
  5 x LTA Cuvette Bar Set à 10 pcs
  1 x Balls 2 mm à 600 pcs
  1 x Silicone Cap à 12 pcs

• LTA 2 reagent with aggregation inductors Arachidonic acid (AA), Adenosine diphosphate (ADP) and Collagen (Col) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP).  
• Standardized reagent combination for special applications
• Lyophilized Arachidonic acid (AA) 20 mM with test application AA 1 mM.
• Lyophilized Adenosine diphosphate (ADP) 100 µM with test application ADP 5 µM.
• Lyophilized Collagen (Col) 50 µg/ml with test application Col 2 µg/ml.
• Diluent, Cleaning solution, cuvettes and balls enclosed in the kit.
• Sufficient for 70 screens
• Stability (reconstituted): 28 days at 2–8°C
• 2 x LTA 2 Reagent Tray (3 x 1 ml)
  2 x LTA Diluent 20 ml
  2 x Clean Pro 15 ml
  3 x LTA Cuvette Bar Set à 10 pcs
  1 x Balls 2 mm à 300 pcs
  1 x Silicone Cap à 12 pcs

• LTA 3 reagent with aggregation inductors Ristocetin (Ris) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP).
• Standardized reagent combination for screening
• Inductor concentrations according to ISTH recommendation
• Lyophilized Ristocetin (Ris) 15 mg/ml with test application Ris 0.6 mg/ml and Ris 1.2 mg/ml.
• Diluent, Cleaning solution, cuvettes and balls enclosed in the kit.
• Sufficient for 60 screens
• Stability (reconstituted): 28 days at 2–8°C
• 2 x LTA 3 Reagent Tray (1 x 1 ml)
  2 x LTA Diluent 20 ml
  2 x Clean Pro 15 ml
  2 x LTA Cuvette Bar Set à 10 pcs
  1 x Balls 2 mm à 200 pcs
  1 x Silicone Cap à 12 pcs

• LTA 4 reagent with aggregation inductors Arachidonic acid (AA), Adenosine diphosphate (ADP), Collagen (Col) and Ristocetin (Ris) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Standardized reagent combination for special applications
• Lyophilized Arachidonic acid (AA) 20 mM with test application AA 1 mM.
• Lyophilized Adenosine diphosphate (ADP) 100 µM with test application ADP 2.5 µM.
• Lyophilized Adenosine diphosphate (ADP) 100 µM with test application ADP 5 µM.
• Lyophilized Collagen (Col) 50 µg/ml with test application Col 2 µg/ml.
• Lyophilized Ristocetin (Ris) 15 mg/ml with test application Ris 0.6 mg/ml.
• Diluent, Cleaning solution, cuvettes and balls enclosed in the kit.
• Sufficient for 70 screens
• Stability (reconstituted): 28 days at 2–8°C
• 2 x LTA 4 Reagent Tray (5 x 1 ml)
  2 x LTA Diluent 20 ml
  2 x Clean Pro 15 ml
  5 x LTA Cuvette Bar Set à 10 pcs
  1 x Balls 2 mm à 600 pcs
  1 x Silicone Cap à 12 pcs

• LTA 5 reagent with aggregation inductors Arachidonic acid (AA), Adenosine diphosphate (ADP), Collagen (Col) and Ristocetin (Ris) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Standardized reagent combination for special applications
• Lyophilized Arachidonic acid (AA) 20 mM with test application AA 1 mM.
• Lyophilized Adenosine diphosphate (ADP) 100 µM with test application ADP 2.5 µM.
• Lyophilized Adenosine diphosphate (ADP) 100 µM with test application ADP 5 µM.
• Lyophilized Collagen (Col) 50 µg/ml with test application Col 2 µg/ml.
• Lyophilized Ristocetin (Ris) 15 mg/ml with test application Ris 1.2 mg/ml.
• Diluent, Cleaning solution, cuvettes and balls enclosed in the kit.
• Sufficient for 50 screens
• Stability (reconstituted): 28 days at 2–8°C
• 2 x LTA 5 Reagent Tray (5 x 1 ml)
  2 x LTA Diluent 20 ml
  2 x Clean Pro 15 ml
  4 x LTA Cuvette Bar Set à 10 pcs
  1 x Balls 2 mm à 600 pcs
  1 x Silicone Cap à 12 pcs

• Aggregation agonist Adenosine-5‘-diphosphate (ADP) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Lyophilized Adenosine-5′-diphosphate; 100 µM
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  ADP 2,5 µM; ADP 5 µM; ADP 10 µM 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml ADP Reagent 100 µM
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Adenosine-5‘-diphosphate (ADP) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Lyophilized Adenosine-5′-diphosphate; 200 µM
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  ADP 5 µM; ADP 10 µM; ADP 20 µM 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml ADP Reagent 200 µM
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Collagen (Col) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Lyophilized Collagen (fibrillar, from horse tendon); 50 µg/ml
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  Col 1 µg/ml; Col 2 µg/ml; Col 5 µg/ml 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml Col Reagent 50 µg/ml
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Collagen (Col) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Lyophilized Collagen (fibrillar, from horse tendon); 100 µg/ml
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  Col 2 µg/ml; Col 5 µg/ml; Col 10 µg/ml 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml Col Reagent 100 µg/ml
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Thrombin receptor-activating peptide (TRAP) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Lyophilized Thrombin receptor PAR-1 activating peptide (S-F-L-L-R-N); 0.5 mM
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  TRAP 10 µM; TRAP 20 µM; TRAP 50 µM 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml TRAP Reagent 0.5 mM
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Thrombin receptor-activating peptide (TRAP) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP). 
• Lyophilized Thrombin receptor PAR-1 activating peptide (S-F-L-L-R-N); 1.0 mM
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  TRAP 20 µM; TRAP 50 µM; TRAP 100 µM 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml TRAP Reagent 1.0 mM
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Epinephrine (Epi) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP).  
• Lyophilized Epinephrine ((R)-1-(3,4-Dihydroxyphenyl)-2-(N-methyl amino)-ethanol), as bitartrate; 100 µM
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  Epi 5 µM; Epi 10 µM
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml Epi Reagent 100 µM  
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Aggregation agonist Ristocetin (Ris) intended for in-vitro determination of platelet aggregation by light transmission aggregometry in platelet rich plasma (PRP).  
• Lyophilized Ristocetin, an antibiotic that agglutinates platelets in the presence of von Willebrand Factor; 15 mg/ml
• Dilution reagent and silicone caps included.
• ThromBash XRA test applications:
  Ris 0,6 mg/ml; Ris 1,2 mg/ml
  Ris 0,5 mg/ml; Ris 1,0 mg/ml 
• Stability (reconstituted): 28 days at 2–8°C
• 2 x 1 ml Ris Reagent 15 mg/ml
  1 x 20 ml LTA Diluent
  1 x 2 Silicone Caps 

• Reagent container for the detection of spontaneous platelet aggregation (SPA) by light transmission aggregometry in platelet rich plasma (PRP) on ThromBash XRA.  
• Container with individual barcode for the measurement of spontaneous platelet aggregation (SPA).
• For filling with 2 ml NaCl 0.9 %; sufficient for 80 tests
• Thrombomate XRA test application
  SPA
• Useability: 2 days on board
• ThromBash LTA SPA Cup á 50pcs.

• Cleaning solution intended for cleaning the needle on Behnk automated systems in order to avoid cross contaminations.  
• Cleaning solution, Sodium hydroxide solution (NaOH), 1 mol/L
• Ready to use reagent suitable for all Behnk automated systems
• Storage at 2-25°C
•  Stability (once opened):
  OBS ThromBash series
  6 days at 16–18°C
  Caped with silicone cap for ThromBash XRA
  28 days on board